Dunn Labortechnik presents a special product range from Porvair Sciences for sample preparation and improved productivity in drug discovery: evaporator, manifold, plate sealer and plates.
https://european-biotechnology.com/wp-content/uploads/2024/04/Dunn_Porvair_Drug_discovery.jpg450800Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2018-03-16 09:36:112024-04-02 15:51:43Equipment, plates and seals from Porvair Sciences for automation in drug discovery
Researchers from Sweden, Switzerland, France, Italy, and Germany report that expression of a post-stroke factor boost arterial plaque formation. The identification of the new target might open up an avenue to prevent embolism and further complications in stroke patients.
At the 11th Berlin Conference, Novo Holdings outlined details of a new €135m investment fund launched to push the development of new drug classes urgently needed to fight antimicrobial resistance. European Biotechnology editors were the first to talk with Aleks Engel, Partner at Novo Holdings, and George Griffin, Chair of the Repair Impact Funds Scientific Advisory Board, about the construction and the goal of the fund.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb2018springaleksengel.jpg450800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-15 12:37:482024-04-02 16:21:28Making an impact on AMR R&D
Researchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist variation in histopathological diagnosis and resulted in a change of diagnoses in up to 12% of prospective cases.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-15 07:26:432018-03-15 07:26:43Algorithm tracks cancer type down to methylation pattern
The tremendous success of last years BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised as a worthy successor.
https://european-biotechnology.com/wp-content/uploads/2024/04/2018_03_14_BIOEuropeSpring.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-14 08:39:272018-03-14 08:39:27Business as usual in Amsterdam
Domainex Ltd, a privately-owned drug discovery services company, has announced the appointment of Dr Bodo Spori as Head of Business Development for Europ.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bodo_Spori_small.jpg400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-03-13 11:39:182018-03-13 11:39:18Domainex appoints Dr Bodo Spori
German MYR Pharma has completed a proof of concept Phase IIb trial with its first-in-class hepatitis D entry inhibitor Myrcludex B, which is developed under the European Medicines Agencys PRIME scheme.
SP Industries Inc. has announced the appointment of Brian Larkin as its President and Chief Executive Officer effective February 19th, replacing William (Bill) Downs who recently retired.
https://european-biotechnology.com/wp-content/uploads/2024/04/brianlarkin_small.png400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-03-12 11:29:002018-03-12 11:29:00SP Industries Announces Brian Larkin as President and CEO
Alirocumab, Sanofi s/Regenerons PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy in 18,924 high-risk patients.
Equipment, plates and seals from Porvair Sciences for automation in drug discovery
ProductsDunn Labortechnik presents a special product range from Porvair Sciences for sample preparation and improved productivity in drug discovery: evaporator, manifold, plate sealer and plates.
Stroke alarmin spurs further embolies
Latest NewsResearchers from Sweden, Switzerland, France, Italy, and Germany report that expression of a post-stroke factor boost arterial plaque formation. The identification of the new target might open up an avenue to prevent embolism and further complications in stroke patients.
Making an impact on AMR R&D
BackgroundAt the 11th Berlin Conference, Novo Holdings outlined details of a new €135m investment fund launched to push the development of new drug classes urgently needed to fight antimicrobial resistance. European Biotechnology editors were the first to talk with Aleks Engel, Partner at Novo Holdings, and George Griffin, Chair of the Repair Impact Funds Scientific Advisory Board, about the construction and the goal of the fund.
Algorithm tracks cancer type down to methylation pattern
Latest NewsResearchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist variation in histopathological diagnosis and resulted in a change of diagnoses in up to 12% of prospective cases.
Business as usual in Amsterdam
Latest NewsThe tremendous success of last years BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised as a worthy successor.
Domainex appoints Dr Bodo Spori
AppointmentsMYR Pharma completes chronic hepatitis delta POC trial
Latest NewsGerman MYR Pharma has completed a proof of concept Phase IIb trial with its first-in-class hepatitis D entry inhibitor Myrcludex B, which is developed under the European Medicines Agencys PRIME scheme.
SP Industries Announces Brian Larkin as President and CEO
AppointmentsSP Industries Inc. has announced the appointment of Brian Larkin as its President and Chief Executive Officer effective February 19th, replacing William (Bill) Downs who recently retired.
Sanofis alirocumab improves cardiovascular event rate over statins
Latest NewsAlirocumab, Sanofi s/Regenerons PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy in 18,924 high-risk patients.
Medimmune finds target against systemic sclerosis
Latest NewsResearchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis.